6-K
File 001-15170
PRIMARY DOCUMENT
- Filing date
- 28 Jul 2025
- Reporting date
- 28 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
GSK plc reports
- Company location
- London
GSK plc has filed 6,806 SEC EDGAR filings since 12 Jan 2001
SEC filing history
Showing 351-375 of 1,000 matching filings.
Per page
25
Current page
15
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 25 Jul 2025
- Reporting date
- 25 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA
- Filing date
- 24 Jul 2025
- Reporting date
- 24 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 24 Jul 2025
- Reporting date
- 24 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
US FDA REVIEW EXTENDED FOR BLENREP
- Filing date
- 23 Jul 2025
- Reporting date
- 23 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 23 Jul 2025
- Reporting date
- 23 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 22 Jul 2025
- Reporting date
- 22 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 21 Jul 2025
- Reporting date
- 21 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 18 Jul 2025
- Reporting date
- 18 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
BLENREP US ODAC OUTCOME
- Filing date
- 18 Jul 2025
- Reporting date
- 18 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 18 Jul 2025
- Reporting date
- 18 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSKS SHINGRIX FULLY LIQUID FDA APPROVAL
- Filing date
- 17 Jul 2025
- Reporting date
- 17 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 17 Jul 2025
- Reporting date
- 17 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 16 Jul 2025
- Reporting date
- 16 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 15 Jul 2025
- Reporting date
- 15 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 15 Jul 2025
- Reporting date
- 15 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
DIRECTOR/PDMR SHAREHOLDING
- Filing date
- 14 Jul 2025
- Reporting date
- 14 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA
- Filing date
- 14 Jul 2025
- Reporting date
- 14 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 14 Jul 2025
- Reporting date
- 14 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 11 Jul 2025
- Reporting date
- 11 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 10 Jul 2025
- Reporting date
- 10 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 09 Jul 2025
- Reporting date
- 09 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 08 Jul 2025
- Reporting date
- 08 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD
- Filing date
- 07 Jul 2025
- Reporting date
- 07 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
6-K
File 001-15170
TRANSACTION IN OWN SHARES
- Filing date
- 07 Jul 2025
- Reporting date
- 07 Jul 2025
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing